1846PRole of TP53 mutations in relation to response to anti-ALK agents in EML4-ALK-translocated NSCLC patients. (23rd October 2018) - Canale, M; Delmonte, A; Dazzi, C; Gamboni, A; Casanova, C; Papi, M; Mariotti, M; De Luigi, N; Burgio, M A; Minuti, G; Calistri, D; Bonafè, M; et al.